Hereditary Cancer Testing Market By Cancer Type (Breast Cancer, Gastric Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer, Other Cancers), By Test Type (Predictive Testing, Diagnostic Testing), By End User (Diagnostic Centers, Hospitals, Clinics): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global hereditary cancer testing market was valued at $3,510.29 million in 2021, and is projected to reach $10,087.49 million by 2031, registering a CAGR of 11.6% from 2022 to 2031.
Genetic testing helps estimate the chance of developing cancer in the lifetime. This can be done by searching for specific changes in the genes, chromosomes, or proteins called mutations. Genetic tests are available for some types of cancer which include breast cancer, ovarian cancer, colon cancer, prostate cancer, pancreatic cancer, kidney cancer and stomach cancer. People who are concerned about whether their family history puts them at risk for cancer should consult with a genetic counselor. The features of personal or family medical history of a person that particularly is in combination, may suggest a hereditary cancer syndrome such as the cancer was diagnosed at an unusually young age or several different types of cancer occurred in the same person. Moreover, hereditary cancer testing can also verify the type of cancer inherited in the person. If a person in the family has already been found to have an inherited cancer susceptibility syndrome, then any family members who could have inherited the variant should consider genetic testing. It is because knowing about the risks may help to prevent a future cancer.
The growth of the hereditary cancer testing market is driven by rise in geriatric population and increase in incidence of cancer across the globe, and surge in the government expenditure on healthcare. Moreover, increase in awareness regarding the hereditary cancer testing and favorable reimbursement policies contribute toward the growth of the market. However, lack of skilled professionals and high cost of the tests are expected to hinder the growth of the market. Conversely, high growth potential in untapped emerging economies is expected to create lucrative opportunities for the market.
The hereditary cancer testing market is segmented on the basis of cancer type, test type, end user, and region. On the basis of cancer type, the market is categorized into breast cancer, gastric cancer, ovarian cancer, prostate cancer, colorectal cancer, other cancers. On the basis of test type, the market is classified into predictive testing and diagnostic testing. On the basis of end user, the market is classified into diagnostic centers, hospitals and clinics. Furthermore, the hospitals segment is sub-classified by type as private and public. On the basis of region, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.
The major companies profiled in the report include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche AG, Illumina, Inc., Myriad Genetics, Inc., Qiagen N.V., Thermo Fisher Scientific, Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the hereditary cancer testing market analysis from 2021 to 2031 to identify the prevailing hereditary cancer testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the hereditary cancer testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global hereditary cancer testing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Cancer Type
Breast Cancer
Gastric Cancer
Ovarian Cancer
Prostate Cancer
Colorectal Cancer
Other Cancers
By Test Type
Predictive Testing
Diagnostic Testing
By End User
Diagnostic Centers
Hospitals
Type
Private
Public
Clinics
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest Of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest Of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest Of LAMEA
Key Market Players
Abbott Laboratories
Bio-Rad Laboratories, Inc.
CSL Ltd.
Danaher Corporation
EUROFINS SCIENTIFIC
F. HOFFMANN-LA ROCHE LTD
Illumina, Inc.
Myriad Genetics, Inc.
Qiagen NV
Thermo Fisher Scientific, Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- 3.7.Patent Landscape
- CHAPTER 4: HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Breast Cancer
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Gastric Cancer
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Ovarian Cancer
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Prostate Cancer
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Colorectal Cancer
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- 4.7 Other Cancers
- 4.7.1 Key market trends, growth factors and opportunities
- 4.7.2 Market size and forecast, by region
- 4.7.3 Market analysis by country
- CHAPTER 5: HEREDITARY CANCER TESTING MARKET, BY TEST TYPE
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Predictive Testing
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Diagnostic Testing
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- CHAPTER 6: HEREDITARY CANCER TESTING MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Diagnostic Centers
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Hospitals
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.3.4 Hospitals Hereditary Cancer Testing Market by Type
- 6.3.4.1 Private Market size and forecast, by region
- 6.3.4.2 Public Market size and forecast, by region
- 6.4 Clinics
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: HEREDITARY CANCER TESTING MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Cancer Type
- 7.2.3 North America Market size and forecast, by Test Type
- 7.2.4 North America Market size and forecast, by End User
- 7.2.4.1 North America Hospitals Hereditary Cancer Testing Market by Type
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Cancer Type
- 7.2.5.1.2 Market size and forecast, by Test Type
- 7.2.5.1.3 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Cancer Type
- 7.2.5.2.2 Market size and forecast, by Test Type
- 7.2.5.2.3 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Cancer Type
- 7.2.5.3.2 Market size and forecast, by Test Type
- 7.2.5.3.3 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Cancer Type
- 7.3.3 Europe Market size and forecast, by Test Type
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.4.1 Europe Hospitals Hereditary Cancer Testing Market by Type
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Cancer Type
- 7.3.5.1.2 Market size and forecast, by Test Type
- 7.3.5.1.3 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Cancer Type
- 7.3.5.2.2 Market size and forecast, by Test Type
- 7.3.5.2.3 Market size and forecast, by End User
- 7.3.5.3 UK
- 7.3.5.3.1 Market size and forecast, by Cancer Type
- 7.3.5.3.2 Market size and forecast, by Test Type
- 7.3.5.3.3 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Cancer Type
- 7.3.5.4.2 Market size and forecast, by Test Type
- 7.3.5.4.3 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Cancer Type
- 7.3.5.5.2 Market size and forecast, by Test Type
- 7.3.5.5.3 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Cancer Type
- 7.3.5.6.2 Market size and forecast, by Test Type
- 7.3.5.6.3 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Cancer Type
- 7.4.3 Asia-Pacific Market size and forecast, by Test Type
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.4.1 Asia-Pacific Hospitals Hereditary Cancer Testing Market by Type
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Cancer Type
- 7.4.5.1.2 Market size and forecast, by Test Type
- 7.4.5.1.3 Market size and forecast, by End User
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Cancer Type
- 7.4.5.2.2 Market size and forecast, by Test Type
- 7.4.5.2.3 Market size and forecast, by End User
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Cancer Type
- 7.4.5.3.2 Market size and forecast, by Test Type
- 7.4.5.3.3 Market size and forecast, by End User
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Cancer Type
- 7.4.5.4.2 Market size and forecast, by Test Type
- 7.4.5.4.3 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Cancer Type
- 7.4.5.5.2 Market size and forecast, by Test Type
- 7.4.5.5.3 Market size and forecast, by End User
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Cancer Type
- 7.4.5.6.2 Market size and forecast, by Test Type
- 7.4.5.6.3 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Cancer Type
- 7.5.3 LAMEA Market size and forecast, by Test Type
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.4.1 LAMEA Hospitals Hereditary Cancer Testing Market by Type
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Cancer Type
- 7.5.5.1.2 Market size and forecast, by Test Type
- 7.5.5.1.3 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Cancer Type
- 7.5.5.2.2 Market size and forecast, by Test Type
- 7.5.5.2.3 Market size and forecast, by End User
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Cancer Type
- 7.5.5.3.2 Market size and forecast, by Test Type
- 7.5.5.3.3 Market size and forecast, by End User
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Cancer Type
- 7.5.5.4.2 Market size and forecast, by Test Type
- 7.5.5.4.3 Market size and forecast, by End User
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Abbott Laboratories
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Bio-Rad Laboratories, Inc.
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 CSL Ltd.
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Danaher Corporation
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 EUROFINS SCIENTIFIC
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 F. HOFFMANN-LA ROCHE LTD
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Illumina, Inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Myriad Genetics, Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Qiagen NV
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 Thermo Fisher Scientific, Inc.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 2. HEREDITARY CANCER TESTING MARKET, FOR BREAST CANCER, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. HEREDITARY CANCER TESTING MARKET FOR BREAST CANCER, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. HEREDITARY CANCER TESTING MARKET, FOR GASTRIC CANCER, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. HEREDITARY CANCER TESTING MARKET FOR GASTRIC CANCER, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. HEREDITARY CANCER TESTING MARKET, FOR OVARIAN CANCER, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. HEREDITARY CANCER TESTING MARKET FOR OVARIAN CANCER, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. HEREDITARY CANCER TESTING MARKET, FOR PROSTATE CANCER, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. HEREDITARY CANCER TESTING MARKET FOR PROSTATE CANCER, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. HEREDITARY CANCER TESTING MARKET, FOR COLORECTAL CANCER, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. HEREDITARY CANCER TESTING MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 12. HEREDITARY CANCER TESTING MARKET, FOR OTHER CANCERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 13. HEREDITARY CANCER TESTING MARKET FOR OTHER CANCERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 14. GLOBAL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 15. HEREDITARY CANCER TESTING MARKET, FOR PREDICTIVE TESTING, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. HEREDITARY CANCER TESTING MARKET FOR PREDICTIVE TESTING, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. HEREDITARY CANCER TESTING MARKET, FOR DIAGNOSTIC TESTING, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. HEREDITARY CANCER TESTING MARKET FOR DIAGNOSTIC TESTING, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. GLOBAL HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 20. HEREDITARY CANCER TESTING MARKET, FOR DIAGNOSTIC CENTERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 21. HEREDITARY CANCER TESTING MARKET FOR DIAGNOSTIC CENTERS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 22. HEREDITARY CANCER TESTING MARKET, FOR HOSPITALS, BY REGION, 2021-2031 ($MILLION)
- TABLE 23. HEREDITARY CANCER TESTING MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 24. GLOBAL HOSPITALS HEREDITARY CANCER TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 25. HEREDITARY CANCER TESTING MARKET, FOR PRIVATE, BY REGION, 2021-2031 ($MILLION)
- TABLE 26. HEREDITARY CANCER TESTING MARKET, FOR PUBLIC, BY REGION, 2021-2031 ($MILLION)
- TABLE 27. HEREDITARY CANCER TESTING MARKET, FOR CLINICS, BY REGION, 2021-2031 ($MILLION)
- TABLE 28. HEREDITARY CANCER TESTING MARKET FOR CLINICS, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 29. HEREDITARY CANCER TESTING MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 30. NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 31. NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 32. NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 33. NORTH AMERICA HOSPITALS HEREDITARY CANCER TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 34. NORTH AMERICA HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 35. U.S. HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 36. U.S. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 37. U.S. HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 38. CANADA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 39. CANADA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 40. CANADA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 41. MEXICO HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 42. MEXICO HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 43. MEXICO HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 44. EUROPE HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 45. EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 46. EUROPE HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 47. EUROPE HOSPITALS HEREDITARY CANCER TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 48. EUROPE HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 49. GERMANY HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 50. GERMANY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 51. GERMANY HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 52. FRANCE HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 53. FRANCE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 54. FRANCE HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 55. UK HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 56. UK HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 57. UK HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 58. ITALY HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 59. ITALY HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 60. ITALY HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 61. SPAIN HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 62. SPAIN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 63. SPAIN HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 64. REST OF EUROPE HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 65. REST OF EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 66. REST OF EUROPE HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 68. ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 69. ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 70. ASIA-PACIFIC HOSPITALS HEREDITARY CANCER TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 71. ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 72. JAPAN HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 73. JAPAN HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 74. JAPAN HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 75. CHINA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 76. CHINA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 77. CHINA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 78. AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 79. AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 80. AUSTRALIA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 81. INDIA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 82. INDIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 83. INDIA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 84. SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 85. SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 86. SOUTH KOREA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 87. REST OF ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 88. REST OF ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 89. REST OF ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 90. LAMEA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 91. LAMEA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 92. LAMEA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 93. LAMEA HOSPITALS HEREDITARY CANCER TESTING MARKET, BY TYPE, 2021-2031 ($MILLION)
- TABLE 94. LAMEA HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 95. BRAZIL HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 96. BRAZIL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 97. BRAZIL HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 98. SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 99. SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 100. SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 101. SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 102. SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 103. SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 104. REST OF LAMEA HEREDITARY CANCER TESTING MARKET, BY CANCER TYPE, 2021-2031 ($MILLION)
- TABLE 105. REST OF LAMEA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2021-2031 ($MILLION)
- TABLE 106. REST OF LAMEA HEREDITARY CANCER TESTING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 107.ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 108.ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 109.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 110.ABBOTT LABORATORIES: NET SALES,
- TABLE 111.ABBOTT LABORATORIES: KEY STRATERGIES
- TABLE 112.BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT
- TABLE 113.BIO-RAD LABORATORIES, INC.: OPERATING SEGMENTS
- TABLE 114.BIO-RAD LABORATORIES, INC.: PRODUCT PORTFOLIO
- TABLE 115.BIO-RAD LABORATORIES, INC.: NET SALES,
- TABLE 116.BIO-RAD LABORATORIES, INC.: KEY STRATERGIES
- TABLE 117.CSL LTD.: COMPANY SNAPSHOT
- TABLE 118.CSL LTD.: OPERATING SEGMENTS
- TABLE 119.CSL LTD.: PRODUCT PORTFOLIO
- TABLE 120.CSL LTD.: NET SALES,
- TABLE 121.CSL LTD.: KEY STRATERGIES
- TABLE 122.DANAHER CORPORATION: COMPANY SNAPSHOT
- TABLE 123.DANAHER CORPORATION: OPERATING SEGMENTS
- TABLE 124.DANAHER CORPORATION: PRODUCT PORTFOLIO
- TABLE 125.DANAHER CORPORATION: NET SALES,
- TABLE 126.DANAHER CORPORATION: KEY STRATERGIES
- TABLE 127.EUROFINS SCIENTIFIC: COMPANY SNAPSHOT
- TABLE 128.EUROFINS SCIENTIFIC: OPERATING SEGMENTS
- TABLE 129.EUROFINS SCIENTIFIC: PRODUCT PORTFOLIO
- TABLE 130.EUROFINS SCIENTIFIC: NET SALES,
- TABLE 131.EUROFINS SCIENTIFIC: KEY STRATERGIES
- TABLE 132.F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
- TABLE 133.F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
- TABLE 134.F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
- TABLE 135.F. HOFFMANN-LA ROCHE LTD: NET SALES,
- TABLE 136.F. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
- TABLE 137.ILLUMINA, INC.: COMPANY SNAPSHOT
- TABLE 138.ILLUMINA, INC.: OPERATING SEGMENTS
- TABLE 139.ILLUMINA, INC.: PRODUCT PORTFOLIO
- TABLE 140.ILLUMINA, INC.: NET SALES,
- TABLE 141.ILLUMINA, INC.: KEY STRATERGIES
- TABLE 142.MYRIAD GENETICS, INC.: COMPANY SNAPSHOT
- TABLE 143.MYRIAD GENETICS, INC.: OPERATING SEGMENTS
- TABLE 144.MYRIAD GENETICS, INC.: PRODUCT PORTFOLIO
- TABLE 145.MYRIAD GENETICS, INC.: NET SALES,
- TABLE 146.MYRIAD GENETICS, INC.: KEY STRATERGIES
- TABLE 147.QIAGEN NV: COMPANY SNAPSHOT
- TABLE 148.QIAGEN NV: OPERATING SEGMENTS
- TABLE 149.QIAGEN NV: PRODUCT PORTFOLIO
- TABLE 150.QIAGEN NV: NET SALES,
- TABLE 151.QIAGEN NV: KEY STRATERGIES
- TABLE 152.THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
- TABLE 153.THERMO FISHER SCIENTIFIC, INC.: OPERATING SEGMENTS
- TABLE 154.THERMO FISHER SCIENTIFIC, INC.: PRODUCT PORTFOLIO
- TABLE 155.THERMO FISHER SCIENTIFIC, INC.: NET SALES,
- TABLE 156.THERMO FISHER SCIENTIFIC, INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.HEREDITARY CANCER TESTING MARKET SEGMENTATION
- FIGURE 2.HEREDITARY CANCER TESTING MARKET,2021-2031
- FIGURE 3.HEREDITARY CANCER TESTING MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.HEREDITARY CANCER TESTING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.PATENT ANALYSIS BY COMPANY
- FIGURE 13.PATENT ANALYSIS BY COUNTRY
- FIGURE 14.HEREDITARY CANCER TESTING MARKET,BY CANCER TYPE,2021(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF BREAST CANCER HEREDITARY CANCER TESTING MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER HEREDITARY CANCER TESTING MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OVARIAN CANCER HEREDITARY CANCER TESTING MARKET,2021-2031(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF PROSTATE CANCER HEREDITARY CANCER TESTING MARKET,2021-2031(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF COLORECTAL CANCER HEREDITARY CANCER TESTING MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF OTHER CANCERS HEREDITARY CANCER TESTING MARKET,2021-2031(%)
- FIGURE 21.HEREDITARY CANCER TESTING MARKET,BY TEST TYPE,2021(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF PREDICTIVE TESTING HEREDITARY CANCER TESTING MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC TESTING HEREDITARY CANCER TESTING MARKET,2021-2031(%)
- FIGURE 24.HEREDITARY CANCER TESTING MARKET,BY END USER,2021(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC CENTERS HEREDITARY CANCER TESTING MARKET,2021-2031(%)
- FIGURE 26.COMPARATIVE SHARE ANALYSIS OF HOSPITALS HEREDITARY CANCER TESTING MARKET,2021-2031(%)
- FIGURE 27.COMPARATIVE SHARE ANALYSIS OF CLINICS HEREDITARY CANCER TESTING MARKET,2021-2031(%)
- FIGURE 28.HEREDITARY CANCER TESTING MARKET BY REGION,2021
- FIGURE 29.U.S. HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 30.CANADA HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 31.MEXICO HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 32.GERMANY HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 33.FRANCE HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 34.UK HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 35.ITALY HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 36.SPAIN HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 37.REST OF EUROPE HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 38.JAPAN HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 39.CHINA HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 40.AUSTRALIA HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 41.INDIA HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 42.SOUTH KOREA HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 43.REST OF ASIA-PACIFIC HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 44.BRAZIL HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 45.SAUDI ARABIA HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 46.SOUTH AFRICA HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 47.REST OF LAMEA HEREDITARY CANCER TESTING MARKET,2021-2031($MILLION)
- FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 52.COMPETITIVE DASHBOARD
- FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 54.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
- FIGURE 55.BIO-RAD LABORATORIES, INC..: NET SALES ,($MILLION)
- FIGURE 56.CSL LTD..: NET SALES ,($MILLION)
- FIGURE 57.DANAHER CORPORATION.: NET SALES ,($MILLION)
- FIGURE 58.EUROFINS SCIENTIFIC.: NET SALES ,($MILLION)
- FIGURE 59.F. HOFFMANN-LA ROCHE LTD.: NET SALES ,($MILLION)
- FIGURE 60.ILLUMINA, INC..: NET SALES ,($MILLION)
- FIGURE 61.MYRIAD GENETICS, INC..: NET SALES ,($MILLION)
- FIGURE 62.QIAGEN NV.: NET SALES ,($MILLION)
- FIGURE 63.THERMO FISHER SCIENTIFIC, INC..: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook